304 related articles for article (PubMed ID: 26424199)
41. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
42. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
43. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
Evers R; Dallas S; Dickmann LJ; Fahmi OA; Kenny JR; Kraynov E; Nguyen T; Patel AH; Slatter JG; Zhang L
Drug Metab Dispos; 2013 Sep; 41(9):1598-609. PubMed ID: 23792813
[TBL] [Abstract][Full Text] [Related]
44. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.
Posada MM; Bacon JA; Schneck KB; Tirona RG; Kim RB; Higgins JW; Pak YA; Hall SD; Hillgren KM
Drug Metab Dispos; 2015 Mar; 43(3):325-34. PubMed ID: 25504564
[TBL] [Abstract][Full Text] [Related]
45. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
[TBL] [Abstract][Full Text] [Related]
46. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
Riley RJ; Wilson CE
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
[TBL] [Abstract][Full Text] [Related]
47. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
Tornio A; Neuvonen PJ; Niemi M; Backman JT
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563
[TBL] [Abstract][Full Text] [Related]
48. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
[TBL] [Abstract][Full Text] [Related]
49. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
50. New therapeutic agents marketed in 1995.
Hussar DA
Pa Med; 1996 Apr; 99(4):43-6. PubMed ID: 8935886
[TBL] [Abstract][Full Text] [Related]
51. The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.
Pan Y; Hsu V; Grimstein M; Zhang L; Arya V; Sinha V; Grillo JA; Zhao P
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S122-31. PubMed ID: 27385170
[TBL] [Abstract][Full Text] [Related]
52. New therapeutic agents marketed in 1993.
Hussar DA
Pa Med; 1994 Jun; 97(6):22-3. PubMed ID: 8065777
[TBL] [Abstract][Full Text] [Related]
53. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade.
Younis IR; Manchandani P; Hassan HE; Qosa H
Clin Pharmacol Ther; 2022 Sep; 112(3):635-642. PubMed ID: 35780478
[TBL] [Abstract][Full Text] [Related]
54. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
55. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
56. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
58. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
59. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
60. Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation.
Hsueh CH; Hsu V; Pan Y; Zhao P
Clin Pharmacokinet; 2018 Oct; 57(10):1337-1346. PubMed ID: 29455429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
